Equities Analysts Issue Forecasts for Tocagen’s Q2 2018 Earnings (TOCA)

Tocagen (NASDAQ:TOCA) – Research analysts at B. Riley issued their Q2 2018 EPS estimates for Tocagen in a report released on Wednesday, May 16th. B. Riley analyst M. Kumar expects that the company will earn ($0.63) per share for the quarter. B. Riley has a “Buy” rating and a $15.00 price target on the stock. B. Riley also issued estimates for Tocagen’s Q3 2018 earnings at $0.17 EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.56) EPS, Q1 2019 earnings at ($0.74) EPS, Q2 2019 earnings at ($0.71) EPS, Q3 2019 earnings at ($0.68) EPS, Q4 2019 earnings at ($0.65) EPS and FY2019 earnings at ($2.61) EPS.

A number of other research analysts also recently weighed in on TOCA. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research raised shares of Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $16.67.

Tocagen stock opened at $9.90 on Friday. Tocagen has a twelve month low of $9.57 and a twelve month high of $9.76. The company has a quick ratio of 5.23, a current ratio of 4.56 and a debt-to-equity ratio of 0.03.

Tocagen (NASDAQ:TOCA) last released its earnings results on Thursday, May 10th. The company reported ($0.65) earnings per share for the quarter. Tocagen had a negative net margin of 109,579.49% and a negative return on equity of 57.09%. The company had revenue of $0.01 million for the quarter.

Several institutional investors have recently added to or reduced their stakes in TOCA. BlackRock Inc. boosted its holdings in Tocagen by 36.4% in the 4th quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after buying an additional 285,396 shares during the period. Lake Street Advisors Group LLC bought a new position in Tocagen in the 4th quarter worth approximately $1,042,000. Artal Group S.A. bought a new position in Tocagen in the 4th quarter worth approximately $1,025,000. Geode Capital Management LLC boosted its holdings in Tocagen by 16.0% in the 4th quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock worth $927,000 after buying an additional 12,472 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Tocagen by 107.4% in the 1st quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock worth $961,000 after buying an additional 41,978 shares during the period. 32.48% of the stock is owned by hedge funds and other institutional investors.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Earnings History and Estimates for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply